Ditchcarbon
  • Contact
  1. Organizations
  2. Nautilus Biotech S.A.
Public Profile
Pharmaceutical Preparation Manufacturing
FR
updated 10 days ago

Nautilus Biotech S.A.

Company website

Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.

DitchCarbon Score

How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

29

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Nautilus Biotech S.A.'s score of 29 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.

51%

Let us know if this data was useful to you

Nautilus Biotech S.A.'s reported carbon emissions

Nautilus Biotech S.A., headquartered in France, currently does not report any specific carbon emissions data. However, the company has set ambitious climate commitments aimed at reducing greenhouse gas (GHG) emissions from its operations. Nautilus Biotech has pledged to achieve a 15% reduction in specific GHG emissions from its pulp and paper mills by 2030, using 2014 as the baseline year. This target applies to both Scope 1 and Scope 2 emissions, reflecting a comprehensive approach to mitigating its environmental impact. While no emissions data is available, these commitments demonstrate Nautilus Biotech's proactive stance on climate action and its dedication to sustainability within the industry. The company is focused on enhancing its operational efficiency and reducing its carbon footprint in alignment with global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Nautilus Biotech S.A.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Nautilus Biotech S.A. is in FR, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Nautilus Biotech S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Neose Technologies, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

OPKO Biologics

IL
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Affymax, Inc.

US
•
Private households with employed persons (95)
Updated 1 day ago

Human Genome Sciences Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 21 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251005.1
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy